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The emergence of resistance of tumour cells to chemotherapy is
one of the obstacles for a more effective treatment of cancer
patients. One form of cellular resistance, directed against a wide
spectrum of natural agents, is referred to as multidrug resistance
(MDR). Among others, the overexpression of drug transporter
proteins, like the MDR1encoded P-glycoprotein (Pgp) (Gottes-
man et al, 1993) and the MRP-1encoded multidrug resistance
protein 1 (MRP1) (Cole et al, 1992, 1998) can cause MDR. These
proteins, which belong to the superfamily of ATP binding cassette
(ABC) transporters (Higgins, 1992), can cause cellular resistance
to agents such as the anthracyclines, the vinca alkaloids and taxol.
Pgp and MRP1 appear to mediate the transport of a broad range of
drugs across cellular membranes (Versantvoort et al, 1992;
Gottesman et al, 1993). Pgp is thought to transport neutral or posi-
tively charged compounds, whereas MRP1 is a transporter of
neutral and anionic compounds such as glutathione-conjugated
drugs, sulphates and glucuronidates (Jedlitschky et al, 1994;
Broxterman et al, 1995). Therefore, MRP1 is considered to be a
multiple organic anion transporter (Jedlitschky et al, 1994; Müller
et al, 1994).
The ATP-dependent transport of anticancer drugs out of tumour
cells that express MDR proteins may at least theoretically lead to
impaired treatment outcome of patients. Therefore, much effort
has been directed at the identification of agents, which inhibit Pgp-
or MRP1-mediated drug transport. Among others, several benzo-
g-pyrones, also called (iso)flavonoids, were found to be able to
modulate Pgp- and MRP1-mediated drug transport in tumour
cell lines (Critchfield et al, 1994; Hooijberg et al, 1997). Many
(iso)flavonoids are present in our daily food, since they are meta-
bolic products of plant species (Kuehnau, 1976). The interest in
these compounds is based on their biochemical activities, such
as phosphotyrosine kinase inhibition (Akiyama et al, 1987;
Glossmann et al, 1981), topoisomerase II inhibition (Markovits et
al, 1989), and scavenging of free radicals (Bors et al, 1987; Cotelle
et al, 1992). Recently, the synthetic compound flavopiridol has
drawn considerable attention for its antiproliferative capacities as
an inhibitor of cyclin-dependent kinases cdk1, cdk2, cdk4 and
cdk7 (Sedlacek et al, 1996). Several phase 1 studies with
flavopiridol are currently in progress (Senderowicz et al, 1998;
Stinson et al, 1998), while several (iso)flavonoids have been
reported to act as inhibitors of angiogenesis, implicating a poten-
tial role in the prevention as well as the treatment of cancer (Fotsis
et al, 1993).
In the past, the (iso)flavonoid genistein was shown to inhibit
the efflux of daunorubicin (DNR) from the MRP1 overexpressing
human small-cell lung cancer GLC4/ADR cells in a competitive
way (Versantvoort et al, 1994). In addition, we recently reported
that the ATPase activity of plasma membranes prepared from
GLC4/ADR cells, but not of parental GLC4 cells, was increased
in the presence of high micromolar concentrations genistein and
several other (iso)flavonoids, among which flavopiridol
(Hooijberg et al, 1997).
In the present work we demonstrate that the specific induction
of MRP1 ATPase activity by the flavonoid flavopiridol, and
other non-glycosylated (iso)flavonoids, is dose-dependent at low
micromolar concentrations. The effects of non-glycosylated
(iso)flavonoids on MRP1 ATPase activity are paralleled by
increasing effects on cellular DNR accumulation in intact MRP1
overexpressing cells. In particular, flavopiridol is shown to modu-
late the DNR accumulation already at low micromolar concentra-
tions. In addition, MRP1 overexpressing cells are found to be
resistant to flavopiridol.
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Chemicals
[3H]GSH (1.6 TBq mmol–1) was from New England Nuclear
(Dreieich, Germany). Dithiothreitol (Sigma, St Louis, MO, USA)
was separated from [3H]GSH according to Butler et al (1976). [3H]
dinitrophenyl-S-glutathione (DNP-SG) was synthesized as described
earlier (Heijn et al, 1997). 1-Chloro-2,4-dinitrobenzene (CDNB) was
from Sigma (St Louis, MO, USA). The flavonoid kaempferol, the
isoflavonoid genistin, malachite green base, ammonium molybdate,
Triton N101, probenecid and ATP were from Sigma (St Louis, MO,
USA). The flavonoids apigenin, apigetrin and kaempferol-3-glucose
were from Extrasynthese (Genay, France). The isoflavonoid genis-
tein was from ICN Biomedicals (Zoetermeer, The Netherlands). The
synthetic flavone derivative flavopiridol (L86-8275, NSC 649890)
(–)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8[4-(3-hydroxy-1-methyl)-
piperidinyl]-4H-benzopyran-4-one was kindly provided by Dr
Böhme (Hoechst Marion Roussel, Cincinnatti, OH, USA). The
(iso)flavonoids were dissolved as a stock solution of 40 mM in
dimethyl sulphoxide (DMSO; Across Chimica, Belgium) and stored
at –20°C. Before experiments, 1:1 dilutions were made in ethanol,
followed by a dilution in ethanol/water (1: 3; v/v) to the appropriate
concentrations. The maximal concentration of DMSO and ethanol,
which was also added to the controls, was 0.5% (v/v). Membrane
filters OE67 were from Schleicher and Schuell (Dassel, Germany).
Doxorubicin hydrochloride was from Laboratoire Roger Bellon
(France). DNR hydrochloride was from Specia (Paris, France) and
[3H]DNR hydrochloride (163 GBq mmol–1) from Dupont de
Nemours (Den Bosch, The Netherlands).
Cell lines
The human small-cell lung cancer cell line GLC4 and its
adriamycin-selected MRP1 overexpressing subline GLC4/ADR
(Zijlstra et al, 1987) were cultured in RPMI-1640 medium (Flow
Labs, Irvine, UK), supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS; Gibco, Paisley, UK). GLC4/ADR cells were
cultured in the presence of 1.2 mM doxorubicin until 7–14 days
before the experiments. The human acute myeloblastic leukaemia
cell line HL-60 and its MRP1 overexpressing subline HL-60/ADR
(Krishnamachary et al, 1994) were cultured as the GLC4 cell line.
HL-60/ADR cells were cultured in the presence of 0.35 mM
doxorubicin, until 7–14 days before the experiments. The non-
small-cell lung cancer cell line SW-1573 and the stable MRP1-
transfected SW-1573 cell line S1(MRP1) and MDR1-transfected
S1(1.1) have been described earlier (Zaman et al, 1995).
S1(MRP1) cells were cultured in the presence of G418 until 2–10
days before experiments.
Plasma membrane vesicles
Plasma membrane vesicles were prepared from parental GLC4 and
drug-resistant GLC4/ADR cells as described (Heijn et al, 1997).
Cells were harvested by centrifugation (275 g, 5 min) and washed
twice in phosphate-buffered saline. Subsequently, the cells were
incubated in 100 mM potassium chloride (KCl), 5 mM magnesium
chloride (MgCl2), 1 mM phenylmethylsulphonyl fluoride and 50 mM
HEPES–KOH (pH 7.4) for 1 h at 0°C, in order to allow the cells to
swell. Then the cells were ultrasonicated at 20% of the maximum
power of an MSE sonicator (Soniprep 150) for three bursts of 15 s.
The suspension was centrifuged at 1500 g for 10 min. The post-
nuclear supernatant was layered on top of a 46% sucrose cushion.
After centrifugation at 100 000 g for 60 min the interface was
removed and washed in 100 mM KC1–50 mM HEPES–5 mM MgCl2
buffer (pH 7.4). The final membrane preparations were stored at
–80°C at a protein concentration of ~ 4 mg ml–1. The enrichment of
Na+K+ATPase was about fivefold (Heijn et al, 1997).
Uptake of substrates into vesicles
Uptake of radiolabelled substrates into vesicles was measured by
rapid filtration as previously described (Heijn et al, 1997). Vesicles
were incubated in KCl–HEPES buffer (pH 7.4) at 37°C (protein
concentration ~ 0.25 mg ml–1), in the presence of 10 mM MgCl2
with or without 1 mM ATP and tritium-labelled DNP-SG. The
reaction was stopped by adding ice-cold KCl–HEPES buffer. After
rapid filtration, the filters were washed twice with KCl–HEPES
buffer. The radioactivity on the filters was measured by liquid
scintillation counting.
ATPase activity determinations
To measure the ATPase activity in plasma membrane fractions we
used a colourimetric method to estimate amounts of inorganic
phosphate (Lanzetta et al, 1979) with some modifications. Plasma
membranes were incubated for 1 h in KCl–HEPES buffer (pH 7.4)
at 37°C, in the presence of 1 mM EGTA, 1 mM sodium azide and
0.1 mM ouabain, with or without 1 mM ATP. The reaction was
linear during this period of time as shown before (Hooijberg et al,
1997). Reactions were stopped by addition of the colour reagent
(0.034% w/v malachite green base, 1.05% w/v ammonium molyb-
date and 0.025% v/v Triton N101). After 1 min, sodium citrate
was added to a final concentration of 3.6% (w/v), in order to
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Figure 1 ATP-dependent uptake of DNP-SG into GLC4 and GLC4/ADR
membrane vesicles and its inhibition by the MIB6 antibody. Plasma
membranes from GLC4 cells (black bars) and GLC4/ADR cells (white bars)
were incubated with 10 nM DNP-SG in the absence or presence of the MIB6
antibody (MIB6) (10 mg ml–1) or an MRP1 control antibody (10 mg ml–1).
Incubation time was 15 s. In the absence of ATP the uptake rate into
GLC4/ADR was comparable to GLC4. Data are means ± s.e.m. (n = 3).
* indicates P-values < 0.05 compared to control (without MIB6) (Student’s
t-test)prevent ATP hydrolysis after having stopped the enzymatic
reaction. Light absorption was measured in an enzyme-linked
immunosorbent assay (ELISA) reader at a wavelength of 595 nm.
No ATP hydrolysis was seen without the addition of membrane
vesicles.
MIB6 antibody and FACS analysis
The preparation and selection of the antibody MIB6 against the
amino acid position 192–360 and 986–1204 of MRP1 will be
described in detail elsewhere (Scheffer et al, in preparation). In
short, anti-MRP1 antibodies were tested for their capacity to inhibit
DNP-SG transport into GLC4/ADR inside-out plasma membrane
vesicles. One monoclonal antibody with potent inhibitory action
was selected and named MRP1 Internal Binding 6 (MIB6). The
isotype of MIB6 was IgM. The specificity of MIB6 for MRP1 was
investigated in a FACS experiment using MRP1-transfected cells
and several couples of MRP1 overexpressing cell lines and their
parental cell lines. GLC4/ADR cells and HL60/ADR cells over-
expressed MRP1, but not MRP2–MRP5 (Kool et al, 1997). Cells
were permeabilized with Becton Dickinson Lysing Solution
containing 0.1% saponin (15 min, room temperature). The earlier
described MRPr1 antibody against MRP1 (Flens et al, 1994) was
used as a control for MRP1 expression, the lmr94 antibody (IgG2a)
(Flens et al, 1994) and a mouse IgM antibody were used as negative
controls. Rabbit–anti-mouse–FITC (fluorescein isothiocyanate) or
rabbit–anti-rat–FITC were used as secondary antibody. The
fluorescence was measured using a FACScalibur flow cytometer.
Cellular drug accumulation
The steady-state cellular drug accumulation of [3H]DNR was
performed as described earlier (Broxterman et al, 1988). The assay
was started by addition of 0.5 mM tritium-labelled DNR in the pres-
ence or absence of a modulator, which was added to the cells 5 min
before DNR. Cells were incubated for 75 min at 37°C, followed
by washing in ice-cold PBS. The amount of radioactivity was
determined by scintillation counting.
Growth inhibition assays
Cells were cultured in either flat-bottom 96-well plates or 24-well
plates. One day after plating drugs were added at different concen-
trations. After 3 days of drug exposure, cells cultured in 24-well
plates were counted using a micro-cellcounter. For cells cultured
in 96-well plates a sulphorhodamine B (SRB) assay was
performed (Skehan et al, 1990).
RESULTS
MIB6 is a specific antibody against MRP1
In order to produce a reagent able to determine the MRP1 speci-
ficity of drug-induced and (iso)flavonoid-induced effects, mono-
clonal antibodies were raised against MRP1 fusion proteins and
selected for their ability to inhibit the ATP-dependent uptake of
DNP-SG into plasma membrane vesicles from MRP1 over-
expressing GLC4/ADR cells. Of 19 MRP1-antibodies tested, only
one inhibited uptake of DNP-SG. This monoclonal antibody was
named MRP1 Internal Binding 6 (MIB6). Figure 1 shows the
effect of MIB6 and one of the other tested MRP1 antibodies on the
ATP-dependent uptake of DNP-SG into plasma membrane vesi-
cles prepared from GLC4/ADR cells and parental GLC4 cells. The
uptake of DNP-SG into GLC4/ADR vesicles was 490 ± 7 pmol mg
protein–1 min–1, using 100 nM DNP-SG. In the presence of MIB6
the uptake was decreased to about 50% of the uptake in the
absence of MIB6. MIB6 had no effect on the uptake of DNP-SG
into GLC4 vesicles.
We further tested the specificity of the MIB6 antibody for MRP1
in several experiments that will be described in detail elsewhere
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Table 2 Effect of (iso)flavonoids on the accumulation of daunorubicin in
GLC4 cells and GLC4/ADR cells
GLC4 GLC4/ADR
Control 100 ± 0 100 ± 0
Genistein 107 ± 7 354a ± 17
Genistin 101 ± 3 96 ± 4
Kaempferol 92 ± 7 190a ± 38
Kaempferol-3 glucose 88a ± 57 6 a ± 8
Apigenin 91 ± 3 220a ± 45
Apigetrin 70a ± 11 57a ± 20
Flavopiridol 104 ± 2 242a ± 62
Table gives mean percentages of control (set at 100%) ± s.e.m. (n = 3).
Concentration (iso)flavonoid was 50 mM. aSignificantly different from control,
P < 0.05 (Student’s t-test).
Table 1 Flow cytometric analysis of MIB6 interaction with MRP1
Cell line Ratio Ratio Ratio Ratio
mrpr1/lmr 94 resistant/parent MIB6/IgM resistant/parent
GLC4 2.8 ± 0.4 9.6 ± 3.2 5.5 ± 1.2 8.9 ± 2.6
GLC4/ADR 27.0± 8.0 49.0 ± 9.7
HL60 1.9 ± 0.2 4.0 ± 0.9 3.9 ± 1.0 4.1 ± 1.2
HL60/ADR 7.6 ± 0.4 16.0 ± 2.5
SW1573 2.7 ± 0.8 3.0 ± 1.3 7.8 ± 5.4 2.6 ± 0.9
S1(MRP) 8.2 ± 2.5 20.0 ± 1.5
Numbers are ratios of mean fluorescence intensities derived from FACS histograms. Antibodies used are MRPr1 (0.35 mg ml–1) and irrelevant lmr94 (both
IgG2a) (Flens et al, 1994), and MIB6 (2 mg ml–1) and irrelevant IgM antibody. GLC4/ADR, HL60/ADR overexpress MRP1(Krishnamachary et al, 1994; Kool et al,
1997). S1(MRP) is a stable MRP1-transfectant of SW1573 (Zaman et al, 1995).(Scheffer et al, in preparation). Here we show the MRP1 specificity
of MIB6 as analysed by flow cytometry using three different pairs
of parent and MRP1 overexpressing cells (Table 1). For compar-
ison we used the established anti-MRP1 antibody MRPr1 (Flens et
al, 1994). Table 1 shows the comparison between the fluorescence
signals of MIB6-labelled cells and MRPr1-labelled cells. It can be
seen that the ratios of the staining of MRP1 overexpressing cells to
parent cells were very similar for both antibodies.
Inhibition of MRP1 ATPase activity by MIB6
The capacity of MIB6 to inhibit DNP-SG-induced stimulation
of the ATPase activity of membranes from GLC4/ADR was
measured. The basal ATPase activity of GLC4/ADR membranes
was stimulated by 10mMDNP-SG to 4.5 ±0.5nmol mg protein–1
min–1 above the control. This was a stimulation of 125% compared
to the control (Figure 2A). In the presence of MIB6, however, the
induction of the ATPase activity of GLC4/ADR membranes by
DNP-SG was significantly lower (107% of control levels).
Next, we investigated the effect of MIB6 on the stimulation of
the ATPase activity of GLC4/ADR membranes by an MRP1 modu-
lator, the isoflavonoid genistein (Figure 2B). The significant
ATPase stimulation by 50mMgenistein to 108% of the control was
almost completely inhibited in the presence of MIB6.
Dose-dependent induction of MRP1 ATPase activity by
(iso)flavonoids
Since we have shown that genistein induces ATPase activity of
MRP1, we tested the dose-dependency of several (iso)flavonoids
on the MRP1 ATPase activity of GLC4/ADR membranes. Because
many naturally occurring (iso)flavonoids are glycosylated
(Kuehnau, 1976), we also investigated the effect of a glucose
substitution on the (iso)flavonoid molecules on their interaction
with MRP1.
GLC4/ADR plasma membranes were incubated with one of
the (iso)flavonoids genistein, genistin (=genistein-7-glucose),
kaempferol, kaempferol-3-glucose, apigenin, or apigetrin (=
apigenin-7-glucose) (see Figures 3 and 4). None of the tested
(iso)flavonoids affected the ATPase activity of parental GLC4
membranes (data not shown). The ATPase activity of GLC4/ADR
membranes was induced significantly by apigenin, kaempferol
and genistein at concentrations as low as 1mMand higher. Only for
kaempferol, at 4 and 8mMno significant effect was observed, for
which we do not have an explanation so far. In contrast to the
ATPase stimulation by the non-glycosylated compounds, the
glycosylated (iso)flavonoids apigetrin, kaempferol-3-glucose and
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Table 3Cytotoxicity of (iso)flavonoids for different MRP1 overexpressing
and parent cell lines
IC50 value
Cell Flavopiridol Genistein Kaempferol
GLC4 45 ±5nMa 12 ±3mMb 25 ±9mMb
GLC4/ADR 128 ±16nMa 13 ±7mMb 11 ±4mMb
GLC4
d > 1000nMa ND ND
GLC4/ADRd > 1000nMa ND ND
SW1573 85 ±4nMc 10 ±3mMc 29 ±5mMc
S1(MRP) 130 ±24nMc 9 ±3mMc 38 ±9mMc
S1(1.1) 93 ±30nMc 9 ±1mMc 43 ±12mMc
aMean ±s.e.m. (n = 3). bMean ±s.e.m. (n = 5). cMean ±s.e.m. (n = 4).
dIncubation of 1h, followed by 71-h drug-free period. ND, not determined.
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Figure 2Inhibition of the ATPase activity of GLC4/ADR membranes by
MIB6. (A) ATPase activity induced by 10mMDNP-SG. (B) ATPase activity
induced by 50mMgenistein. Concentration MIB6 was 10mg ml–1. Data are
means ±s.e.m. (n = 3). * P < 0.05 compared to control (Student’s t-test)
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Figure 3Structure of (iso)flavonoids used in this study. Rings of the basic
structure referred to in the Discussion are indicated with A or B. Flavonoids
used were: apigenin (R3 = H; R7=OH), apigetrin (R3 = H; R7=glucose),
kaempferol (R3=OH; R7=OH), kaempferol-3-glucose (R3 = glucose;
R7 = OH) and flavopiridol. Isoflavonoids used were: genistein (R7 = OH)
and genistin (R7 = glucose)genistin did not induce ATPase activity in the concentration range
tested (Figure 4).
We were particularly interested in the MRP1-interaction of the
synthetic anticancer agent flavopiridol. Flavopiridol stimulated the
MRP1 ATPase activity at concentrations of 1 mM and higher, as
shown in Figure 5. The MIB6 antibody inhibited this flavopiridol-
induced ATPase activity almost completely (Figure 5).
Since it has been demonstrated that several uncharged and basic
compounds can be transported by MRP1 only in the presence of
millimolar concentrations of reduced glutathione (GSH) (Loe et al,
1997, 1998), we studied the effect of GSH on (iso)flavonoid-
induced MRP1 ATPase activity. In the presence of GSH (0.5 mM
or 5 mM) no synergistic stimulation of ATPase activity could be
observed for flavopiridol, as well as other flavonoids (data not
shown).
Effect of flavopiridol and other (iso)flavonoids on the
accumulation of DNR in MRP1-overexpressing cells
Earlier reports described the modulation of MRP1-mediated drug
transport out of cells by high concentrations of genistein
(Versantvoort et al, 1994). We studied whether flavopiridol and
other (iso)flavonoids also affected cellular drug accumulation and
whether this paralleled the described effects on MRP1 ATPase
activity. The effect of a moderate concentration (50 mM) of
(iso)flavonoids on the accumulation of DNR in GLC4 and
GLC4/ADR was measured (Table 2). In the parental GLC4 cells, no
(iso)flavonoid effect on the DNR accumulation was observed.
However, genistein, kaempferol, apigenin and flavopiridol signifi-
cantly increased the accumulation of DNR in GLC4/ADR cells. In
contrast, the glycosylated compounds genistin, kaempferol-3-
glucose and apigetrin did not increase accumulation of DNR in
GLC4/ADR cells. A small, but significant decrease of the DNR
accumulation was seen in both cell lines for kaempferol-3-glucose
and apigetrin, which points to a non-MRP1 related effect.
Since flavopiridol is currently being tested as an anticancer
agent at low mM doses (Senderowicz et al, 1998; Stinson et al,
1998), we were particularly interested whether flavopiridol was
able to modulate MRP1 function at much lower concentrations
as well. We therefore tested a wider range of concentration
flavopiridol from 100 nM to 50 mM and compared its effect on
cellular DNR accumulation with that of genistein. Figure 6 gives
the modulation of the accumulation of DNR in GLC4/ADR cells
by both compounds at concentrations lower than 10 mM. Already
at the lowest concentration tested (100 nM) we observed a signifi-
cant increase of DNR accumulation by flavopiridol. In contrast,
low micromolar concentrations of genistein (and other flavonoids,
data not shown) did not modulate the cellular accumulation of
DNR in these cells.
Growth inhibition by (iso)flavonoids of MRP1
overexpressing cells compared to drug-sensitive cells
We wanted to obtain information on the potential impact of MRP1
expression on the growth inhibitory effects of flavopiridol,
genistein and kaempferol. For that, we tested these compounds on
GLC4 and GLC4/ADR cells, SW1573, their MRP-1 transfectant
S1(MRP1) and their MDR1 transfectant S1(1.1) (Zaman et al,
1995) (Table 3). First, it can be seen that flavopiridol is about 100-
fold more potent compared to both other compounds. In addition,
we observed resistance against flavopiridol in the GLC4/ADR cells
(2.8 times resistant compared to GLC4) and in S1(MRP) cells (1.5
times resistant compared to SW1573). Simultaneous incubation
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Figure 4 Effect of (iso)flavonoids and glycosylated (iso)flavonoids on MRP1
associated ATPase activity. Data are means of at least three different
experiments. Error bars are included if P-values < 0.05 compared to control
(Student’s t-test). Lines given are fitted (least squares method). (A) Induction
by apigenin (filled symbols) and apigetrin (open symbols). (B) Induction by
kaempferol (filled symbols) and kaempferol-3-glucose (open symbols).
(C) Induction by genistein (filled symbols) and genistin (open symbols)
Figure 5 Effect of flavopiridol on the MRP1-associated ATPase activity.
Tested concentrations of flavopiridol were: 0 mM (control), 0.5, 1, 2, 4, 8, 16,
32, 50 and 100 mM (filled symbols). At 32 mM, 50 mM and 100 mM the effect of
the MIB6 antibody (10 mg ml–1) is shown (open symbols). Data are means of
three independent experiments. * indicates P-values < 0.05 compared to
control (Student’s t-test). The line was fitted with a least square methodwith the established MRP1 inhibitor probenecid (Feller et al,
1995) (0.5 mM) did not alter the cytotoxic effect of flavopiridol on
GLC4 cells and GLC4/ADR cells (data not shown). Short expo-
sures (1 h) of flavopiridol to GLC4 cells and GLC4/ADR cells,
followed by a drug-free culture period (71 h) resulted in IC50
values above 1 mM for both cell lines. No resistance against geni-
stein and kaempferol (72-h exposures) could be observed. Also,
the MDR1-transfected S1(1.1) cells showed no resistance against
either of the (iso)flavonoids.
DISCUSSION
The multidrug resistance protein MRP1 seems to be expressed in
all human cancers (Nooter et al, 1995). High levels of MRP1
expression have been found in chronic lymphocytic leukaemia,
oesophagus squamous cell carcinoma and non-small-cell lung
cancer (Nooter et al, 1995). Modulation of MRP1-mediated drug
transport may be one way to improve the efficiency of chemother-
apeutic treatment of cancer. One class of chemicals that has been
reported to interact with MRP1 is the group of (iso)flavonoids
(Versantvoort et al, 1993; Hooijberg et al, 1997). The interest in
these compounds exceeds their use as MDR modulators, because
of their broad spectrum of biochemical activities and their occur-
rence in our daily food as metabolic products of plants. Although
in the past, several estimations have been made of the daily human
intake of (iso)flavonoids (Kuehnau, 1976) these data are still a
matter of dispute, due to lack of sensitivity of the analytical
methods (Hollman et al, 1995). Recent reports showed that the
synthetic flavonoid flavopiridol could reach steady-state plasma
concentrations in humans of 200–300 nM during continuous
infusion (Senderowicz et al, 1998; Stinson et al, 1998).
A number of biochemical activities have been described for some
(iso)flavonoids, which relate to their effects on tumour cell prolifer-
ation. These biochemical activities include inhibition of phospho-
tyrosine kinases (Akiyama et al, 1987) and inhibition of
topoisomerase II (Markovits et al, 1989). But also inhibition of
angiogenesis has been described (Fotsis et al, 1993). Finally, certain
(iso)flavonoids, in particular the synthetic flavonoid flavopiridol,
have been reported to be specific inhibitors of cyclin-dependent
kinases (Carlson et al, 1996; Sedlacek, 1996). In this respect,
flavopiridol is 250-fold more potent compared to genistein and
quercetin (Losiewicz et al, 1996). Therefore, flavopiridol is now the
first potent cyclin-dependent kinase inhibitor to undergo clinical
trials as an antineoplastic agent (Senderowicz et al, 1998; Stinson et
al, 1998).
In this study we have performed an analysis of the effects of
flavopiridol on MRP1 activity, and compared it with some of the
typical members of the large group of natural (iso)flavonoids.
Based on an earlier study (Hooijberg et al, 1997) we knew that
flavopiridol and several natural (iso)flavonoids stimulate the
ATPase activity of MRP1 containing GLC4/ADR plasma
membranes at relatively high micromolar concentrations. Two
important considerations made us decide to study here the
specific interaction of low micromolar concentrations of the
(iso)flavonoids on MRP1 activity. First, in the light of the common
intake with food, many (iso)flavonoids and their metabolites are
present in low concentrations in human plasma (Hollman et al,
1997). Thus, the possibility that low plasma concentrations of
many inhibitory compounds on MRP1 activity may act in an addi-
tive way must be considered. This has been described previously
for Pgp modulators (Lyumbimov et al, 1995). Secondly, in
particular with regard to flavopiridol, current clinical trials have
achieved maximum tolerated doses of approximately 200–300 nM
with a continuous infusion scheme (Senderowicz et al, 1998;
Stinson et al, 1998).
In this study we have used plasma membrane vesicles from
drug-resistant MRP1 overexpressing GLC4/ADR cells to investi-
gate MRP1-related ATPase activity and drug transport. As a tool to
determine the MRP1 specificity of the (iso)flavonoid effects on
transport and ATPase activity we have used a new monoclonal
antibody against MRP1. This antibody, MIB6, supposedly binds
to MRP1 at an internal epitope in intact membranes, since we
observed interaction of this antibody with MRP1 in flow
cytometry after membrane permeabilization and in immunopre-
cipitation experiments, but not on Western blots. Our results show
that the ATP-dependent uptake of the MRP1 substrate DNP-SG in
GLC4/ADR plasma membrane vesicles, as well as the ATPase
activity of GLC4/ADR membranes induced by DNP-SG or
(iso)flavonoids could be inhibited by MIB6.
We showed that several (iso)flavonoids, among which
flavopiridol, stimulated MRP1 ATPase activity at low micromolar
concentrations. Since this stimulation of ATPase activity was inhib-
ited by MIB6, it was MRP1 specific. Stimulation of MRP1 ATPase
activity has also been described by Chang et al (1997). The latter
authors showed a rather small ATPase stimulation of semi-purified
MRP1 by the substrates daunorubicin and doxorubicin. Addition of
reduced GSH to these compounds resulted in an apparantly syner-
gistic increase of ATPase stimulation. Besides, recent reports by
Loe et al (1997, 1998) showed a GSH-dependent MRP1-mediated
transport of basic, uncharged compounds. In our study, however,
simultaneous incubation with GSH did not result in a synergistic
increase of flavonoid-induced MRP1 ATPase activity.
Although much interest is directed towards non-glycosylated
(iso)flavonoids, glycosylated flavonoids are in fact the most abun-
dant species present in plants (Kuehnau, 1976). It was believed
that these compounds could not be taken up in the intestine before
deglycosylation by the intestinal flora (Bokkenheuser et al, 1987).
However, recently it has been shown that glycosides of
(iso)flavonoids can be detected in human plasma (Hollman
et al, 1995, 1997). Therefore, we also explored the effects of
glycosylated (iso)flavonoids on MRP1 activity. The glycosylated
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Figure 6 Effect of flavopiridol (closed symbols) and genistein (open
symbols) on daunorubicin accumulation in GLC4/ADR cells. Data are means
± s.e.m. (n = 3). The tested concentrations were: 0 mM (control), 0.1 mM, 1 mM,
5 mM and 10 mM. All tested flavopiridol concentrations and 10 mM genistein
gave a significant difference (*) from the control (P < 0.05, Student’s t-test).
Lines given are fitted (least square method)(iso)flavonoids tested appeared unable to increase DNR accumula-
tion in MRP1-overexpressing tumour cells, compared to the
parent cells. This lack of enhancing effect of the glycosylated
(iso)flavonoids on cellular DNR accumulation cannot be
explained exclusively by a slow membrane passage of these
compounds, since also the ATPase activity of MRP1 containing
inside-out plasma membrane vesicles was not affected by the
glycosylated (iso)flavonoids. Together, these observations
concerning glycosylated (iso)flavonoids and their aglycones point
to intrinsic differences in interaction with MRP1 between both
classes of (iso)flavonoids.
When the tested compounds are examined in detail (Figure 3) it
appears that the presence of a glucose moiety on position R7 of the
A-ring of the (iso)flavonoid prevents the interaction with MRP1.
However, since kaempferol-3-glucose also lacks an effect, it does
not seem to be simply steric hindrance or the loss of two hydroxyl
groups on the A-ring that is the cause. Moreover, the presence of
the hydroxy-methyl-piperidinyl group on the A-ring of flavopiridol
does not prevent MRP1 ATPase stimulation. Thus, not simply any
substitution on this ring abolishes activity. Clearly, more extensive
structure–activity analysis has to be done in order to define the
exact structural requirements for (iso)flavonoid–MRP1 interaction.
Also, it should be considered that effects on ATPase activity are not
necessarily paralleled by similar effects on transport.
An interesting aspect of this study with respect to experimental
cancer treatment is the fact that flavopiridol seems to be more
potent as an inhibitor of MRP1-mediated drug transport than the
other tested (iso)flavonoids (Versantvoort et al, 1993; present
study). Natural non-glycosylated (iso)flavonoids were able to
increase cellular DNR accumulation, only when present at high
micromolar concentrations. However, a concentration as low as
100 nM flavopiridol affected DNR accumulation in MRP1-over-
expressing cells. This concentration was lower than can be reached
in human plasma during continuous infusion (Senderowicz et al,
1998; Stinson et al, 1998).
Since flavopiridol is proposed and tested not only as a single agent,
but also in combination treatment with various anticancer drugs
(Bible et al, 1997), our present data suggest that in future develop-
ment of therapies with flavopiridol one should consider the inter-
actions of this compound with MRP1 and its possible potentiation of
MRP1 substrates, such as daunorubicin, vincristine and etoposide.
On the other hand, a somewhat decreased activity of flavopiridol as
single agent against MRP1-overexpressing tumours might be antici-
pated from the cross-resistance data presented in this study.
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